ASCO 2017 - Chronic Lymphocytic Leukemia

A phase 2 study was conducted to examine the efficacy and safety of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) for previously untreated patients with mutated IGHV chronic lymphocytic leukemia (CLL).
This phase 2 study evaluates the efficacy and safety of bendamustine and obinutuzumab as first-line treatment for patients with chronic lymphocytic leukemia (CLL). 
A phase 1 study evaluates the efficacy and toxicity of the combination of ibrutinib and buparlisib in relapsed/refractory non-Hodgkin lymphoma.
The phase 2 KI Intolerance Study was undertaken to assess the safety and efficacy of TGR-1202, a next-generation, highly specific PI3Kδ inhibitor, in patients with chronic lymphocytic leukemia (CLL).
A phase 1 study explores a combination of a novel Bruton’s tyrosine kinase (BTK) inhibitor, DTRMWXHS-12 (DTRM-12), with everolimus and pomalidomide in patients with chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma.
The multicenter, randomized, double-blind, placebo-controlled phase 3 PERSPECTIVE study compares the progression-free survival outcomes of ibrutinib with rituximab versus placebo with rituximab in patients with treatment-naïve (TN) follicular lymphoma (FL).
The pilot trial of anti-CD19 chimeric antigen receptor (CAR) T-cells with ibrutinib assessed complete remission in patients with chronic lymphocytic leukemia (CLL).
The phase 2 AIM study examined the efficacy and safety of the combination of ibrutinib and venetoclax in relapsed/refractory mantle-cell lymphoma (MCL).
A quantitative analysis revealed substantially different activity profiles for ibrutinib and chlorambucil in the circulating cells during the first year of treatment in patients with chronic lymphocytic leukemia (CLL).
This 2-cohort, phase 2 study will investigate a CD19 antibody, MOR208, combined with idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were previously treated with a Bruton’s tyrosine kinase inhibitor.
Page 1 of 2
Results 1 - 10 of 16
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME